1. Home
  2. BDSX vs CUE Comparison

BDSX vs CUE Comparison

Compare BDSX & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Biodesix Inc.

BDSX

Biodesix Inc.

HOLD

Current Price

$7.95

Market Cap

53.0M

Sector

Health Care

ML Signal

HOLD

Logo Cue Biopharma Inc.

CUE

Cue Biopharma Inc.

HOLD

Current Price

$0.47

Market Cap

49.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BDSX
CUE
Founded
2005
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Precision Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
53.0M
49.6M
IPO Year
2020
2018

Fundamental Metrics

Financial Performance
Metric
BDSX
CUE
Price
$7.95
$0.47
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
2
Target Price
$32.50
$3.00
AVG Volume (30 Days)
63.1K
249.2K
Earning Date
11-03-2025
11-12-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$80,173,000.00
$7,100,000.00
Revenue This Year
$20.75
$36.58
Revenue Next Year
$25.05
$32.10
P/E Ratio
N/A
N/A
Revenue Growth
22.29
N/A
52 Week Low
$3.44
$0.47
52 Week High
$32.20
$1.75

Technical Indicators

Market Signals
Indicator
BDSX
CUE
Relative Strength Index (RSI) 52.12 29.93
Support Level $7.77 $0.47
Resistance Level $8.38 $0.51
Average True Range (ATR) 0.57 0.05
MACD -0.01 -0.01
Stochastic Oscillator 60.38 10.78

Price Performance

Historical Comparison
BDSX
CUE

About BDSX Biodesix Inc.

Biodesix Inc is a diagnostic solutions company with a focus in lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources, providing diagnostic testing services associated with blood-based lung and Covid tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics.

About CUE Cue Biopharma Inc.

Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.

Share on Social Networks: